HomeAbout

TL;DR CNBC


Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages - TL;DR CNBC

Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages

Publishing timestamp: 2023-12-05 13:15:25


Summary

Eli Lilly's weight loss treatment, Zepbound, is now available at pharmacies in the US. It serves as an alternative to rival obesity drugs that are facing supply issues. Zepbound is the latest entrant in the growing weight loss drug market, which is expected to reach $100 billion by the end of the decade. Eli Lilly's commercial savings card program is also available to patients, offering discounted prices for Zepbound. The drug works by activating two hormones in the body to suppress appetite and make people feel full for longer.


Sentiment: NEUTRAL

Tickers: LLYNOVO.B-DKCI

Keywords: biotech and pharmaceuticalsbreaking newseli lilly and conovo nordisk a/sbiotechnologybusiness newshealth care industrybusinesspharmaceuticalscigna corp

Source: https://www.cnbc.com/2023/12/05/eli-lilly-weight-loss-drug-zepbound-available-at-us-pharmacies.html


Developed by Leo Phan